Clinical Trial Search

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement — .143; .959 Proportion of Cytuity Cell Samples

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Dose Limiting Toxicity (DLT) — 2; 3; 4 Dose Limiting Toxicities

Primary: To Determine if the LigaSure Device, Which we Routinely Used for Removal of Tubes and Ovaries, is Effective at Destroying All Tubal Cells Comprising the Fallopian Tube…

Primary: Overall Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors and by Rustin's Criteria (RECIST) — 4; 5; 9; 4 Participants

Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants

Primary: Overall Response Rate — .083 proportion of participants

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants

Primary: Progression-free Survival — 2.6; 2.9 months

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria — 9; 0 participants

Primary: Complete and Partial Response Rate Using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 2; 11; 1; 8 participants

Primary: Clinical Response Benefit (Modified Gynecologic Cancer InterGroup [GCIG] Cancer Antigen [CA]-125 Response or Stable Disease) Based on the Response Evaluation Criteria in…

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Progression-free Survival (PFS) at 6-months — 28 percentage of participants

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Tumor Response — 23.4 Percentage of participants

Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001

Primary: PFS — 29.8 Months

Primary: Maximum Tolerated Dose of VEGF Trap (Phase I) — 6 mg/kg

Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells

Primary: Overall Objective Response — 10; 13; 11; 4 participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Number of Participants With Treatment Success — 23 Participants